| Muscular Atrophy |
0 |
0.85 |
| Amyotrophic Lateral Sclerosis |
0 |
1 |
| Food and Drug Administration (FDA) |
0 |
0.95 |
| Patient Safety |
0 |
0.37 |
| Adverse Effects |
0 |
0.35 |
| Oxidative Stress |
0 |
0.17 |
| Bruise |
0 |
0.12 |
| Clinical Research |
0 |
0.12 |
| Dyspnea |
0 |
0.12 |
| Fatigue |
0 |
0.12 |
| Grant |
0 |
0.12 |
| Headache |
0 |
0.12 |
| Healthcare and Medical Technology |
0 |
0.12 |
| Intravenous |
0 |
0.12 |
| Orphan Drugs |
0 |
0.12 |
| Stress |
0 |
0.12 |
| Urticaria |
0 |
0.12 |
| Urticaria and Angioedema |
0 |
0.12 |